Search Results 551-560 of 17846 for Coagulation

1. Investigational Trial To Evaluate XC001 Delivered Via An Cardiac Catheter In Subjects With Chronic Angina. - Mayo Clinic

   Documented active proliferative retinopathy from any cause (ETDRS \[Early Treatment Diabetic Retinopathy Study\] score \>35). 8. Uncontrolled coagulation ...

2. A Study to Evaluate Intravenous Iloprost in Subjects with Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis - Mayo Clinic

   Subjects with a risk of clinically significant bleeding events, including those with coagulation or platelet disorders at screening. Subjects with a history ...

3. Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant - Mayo Clinic

   Patient has adequate bone marrow and coagulation function as shown by the following laboratory values: Absolute Neutrophil Count (ANC) ≥ 1.5 x 10^9/L ...

4. Publications - Ryan M. Chadha, M.D. - Mayo Clinic

   Quantra: A step forward in intraoperative coagulation management, or just the same old test? Liver Transpl 2023 Nov 1; 29 (11):1149-1150 Epub 2023 June 27

5. Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL - Mayo Clinic

   Have acceptable coagulation status: Activated partial thromboplastin (aPTT) and prothrombin time (PT) ≤1.5 × ULN. Have a negative pregnancy test (if female ...

6. Z-Endoxifen Hydrochloride in Treating Patients with Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer - Mayo Clinic

   Active DVT and/or PE requiring anti-coagulant therapy. Patients who are on anti-coagulant therapy for maintenance are eligible as long as the DVT and/or ...

7. Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients with Resected Pancreatic Cancer (the "Apact" Study) - Mayo Clinic

   Acceptable coagulation studies as demonstrated by Prothrombin Time (PT) and Partial Thromboplastin Time (PTT) within normal limits (±15%). Exclusion Criteria ...

8. A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma - Mayo Clinic

   Adequate hematologic, organ, and coagulation within 2 weeks (14 days) prior to randomization. Left ventricular ejection fraction (LVEF) ≥50% assessed ...

9. A Study to Assess Omega-3 Replacement With Krill Oil in Disease Management of System Lupus Erythematosus (SLE) - Mayo Clinic

   Participation eligibility · Stable Grade 3 partial thromboplastin time (PTT) due to lupus anticoagulant and not related to liver disease or anti-coagulant ...

10. Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies - Mayo Clinic

    AZD0466; concurrent anti-coagulation therapy, including aspirin and heparin, which cannot be stopped; medications with known risk of Torsades de Pointes ...